← Leaderboards
Russell Christian Rockne
Beckman Research Institute/City Of Hope
$4,281,270
Attributed
$13,256,534
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,256,534 · 6
By mechanism
U01$7,765,814 · 3
R01$5,317,720 · 2
R03$173,000 · 1
Top collaborators
- Ya-Huei Kuo7 shared
- Guido Marcucci7 shared
- Christine Brown5 shared
- Peter Poon-Hang Lee5 shared
- Jennifer M Munson5 shared
- Flavia Pichiorri5 shared
- Andrei Rodin5 shared
- John E. Shively5 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Guido Marcucci$19,718,636
- Xiuli Wang$2,702,470
- Jeffrey Y Wong$4,970,582
- Margarita Gutova$1,397,878
Others in their field
Other Emerging Leaders on “Mathematical Model”
- Jacob Ruff · Cornell University$14,750,000
- Elke Arenholz · Cornell University$14,750,000
- Peter John Hunter · University Of Auckland$10,288,658
- Anna Bershteyn · New York University School Of Medicine$9,111,180
- Deanna A Kulpa · Emory University$8,444,989
- Gonzalo Martin Vazquez Prokopec · Emory University$6,397,224
Research focus
Mathematical ModelMalignant NeoplasmsCellsMathematicsImmuneClinically RelevantPredictive ModelingClinicTranslatingMouse ModelTreatment OptimizationTumorBiologicalNeoplastic CellTreatment EfficacyStructureIn VivoImmune ResponseChimeric Antigen Receptor T CellsCitiesImmune SystemHigh DimensionalityMathematical MethodsBase
Grant awards (24)
The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy$652,200
R01 · FY2025 · NS
State-transition and leukemia potential dynamics to inform disease evolution and adaptive therapy$590,960
U01 · FY2025 · CA · contact PI
The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy$637,292
R01 · FY2024 · NS
Information flow and state transitions at the system and multi-dimensional scales in leukemia progression$623,198
U01 · FY2024 · CA · contact PI
State-transition and leukemia potential dynamics to inform disease evolution and adaptive therapy$590,960
U01 · FY2024 · CA · contact PI
Information flow and state transitions at the system and multi-dimensional scales in leukemia progression$700,616
U01 · FY2023 · CA · contact PI
The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy$664,834
R01 · FY2023 · NS
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$394,548
R01 · FY2023 · CA
Experimental-Computational Synthesis of Altered Immune Signaling in Breast Cancer$183,872
U01 · FY2023 · CA
Information flow and state transitions at the system and multi-dimensional scales in leukemia progression$863,194
U01 · FY2022 · CA · contact PI
The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy$671,774
R01 · FY2022 · NS
Experimental-Computational Synthesis of Altered Immune Signaling in Breast Cancer$612,300
U01 · FY2022 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$394,548
R01 · FY2022 · CA
Experimental-Computational Synthesis of Altered Immune Signaling in Breast Cancer$921,294
U01 · FY2021 · CA
Information flow and state transitions at the system and multi-dimensional scales in leukemia progression$714,914
U01 · FY2021 · CA · contact PI
The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy$694,724
R01 · FY2021 · NS
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$402,600
R01 · FY2021 · CA
Information flow and state transitions at the system and multi-dimensional scales in leukemia progression$714,914
U01 · FY2020 · CA · contact PI
Experimental-Computational Synthesis of Altered Immune Signaling in Breast Cancer$624,796
U01 · FY2020 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$402,600
R01 · FY2020 · CA
Experimental-Computational Synthesis of Altered Immune Signaling in Breast Cancer$624,796
U01 · FY2019 · CA
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myeloma$402,600
R01 · FY2019 · CA
Development and validation of a computational prediction model for exogenous neural stem cell migration to sites of brain tumors$86,500
R03 · FY2019 · CA · contact PI
Development and validation of a computational prediction model for exogenous neural stem cell migration to sites of brain tumors$86,500
R03 · FY2018 · CA · contact PI